GLP-1 receptor agonist use in adults with concurrent type 2 diabetes and obesity was associated with increased risk for osteoporosis, gout and osteomalacia vs. a matched control group, according to ...

Experts from leading obesity organizations have published recommendations affirming the effectiveness, safety and appropriateness of weight-loss drugs for long-term use.According to a press release, ...

Shoulder replacement is the third most common joint-replacement surgery in the U.S. and is likely to become more common as ...

Long-acting injectable CAB+RPV maintains high virologic suppression in patients with HIV and obesity, showing comparable real-world efficacy.

Mario Ciccarello, 34-year-old fitness fanatic and warehouse worker from Florida, blamed his sudden chest pain on eating spicy ...

Armpit pain in men and women can occur due to muscle strain infections or swollen lymph nodes An expert explains the causes symptoms and when to see a doctor ...

Eli Lilly on Monday launched a new form of its blockbuster obesity drug, Zepbound, that offers a month's worth of doses in a single pen. The pen could serve as a more convenient option for some ...

CagriSema shows 23% weight loss versus 25.5% for Zepbound Novo's shares drop 15% Lilly's shares rise 4% in US pre-market trading Outcome is 'worst-case scenario' for Novo, investor says Few analysts ...

With the obesity market projected to exceed $130 billion by 2034, many major pharmaceutical players are rapidly advancing pipelines to capitalize on what is arguably the most dynamic space in the ...